Table 3 The Synergistic effects on Nrf2 of phenolic compounds associated with other anticancer agents
From: Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy
Type of anticancer agent/treatment associated with phenolic compounds | Experimental Model | Potential Mechanisms | Synergistic effect | Ref |
|---|---|---|---|---|
Chrysin (5,7-dihydroxy flavone) | in vitro BEL-7402 doxorubicin resistant hepatocellular carcinoma cells IC50 = 10, 20 μM | ↓ Nrf2 ↓mRNA ↓PI3K-Akt ↓ERK | sensitize cancer cells to doxorubicin ↑cytotoxicity | [118] |
Luteolin (3,4,5,7-tetrahydroxy flavone) | in vitro HCT116-OX SW620-OX oxaliplatin-resistant colorectal cancer cells IC50 = 1, 5—10 μM | ↓ Nrf2 ↓HO-1 ↓NQO1 ↓GSTα1/2 | sensitize cancer cells to oxaliplatin ↑cytotoxicity | [119] |
3',4',5',5,7-pentamethoxyflavone | in vitro A549 cisplatin-resistant lung cancer cells IC50 = 10–400 μM | ↓ Nrf2 ↓siRNA ↓HO-1 ↓NQO1 ↓GCLC | sensitize cancer cells to cisplatin ↑apoptosis | [120] |
resveratrol and clofarabine | in vitro MSTO-211H mesothelioma cells IC50 = 15 μM | ↓ Nrf2 ↓HO-1 | ↓cancer cells growth ↑apoptosis | [121] |
radiotherapy | - | ↓ Nrf2 ↑ROS | radiosensitivity of cancer cells | Wang et al. [122] |